SwePub
Sök i LIBRIS databas

  Utökad sökning

WFRF:(Flogegård Max)
 

Sökning: WFRF:(Flogegård Max) > (2019) > Autoimmune disease ...

Autoimmune disease in patients with diffuse large B-cell lymphoma : occurrence and impact on outcome

Mörth, Charlott (författare)
Uppsala universitet,Centrum för klinisk forskning i Sörmland (CKFD),Experimentell och klinisk onkologi
Valachis, Antonis, 1984- (författare)
Örebro universitet,Institutionen för medicinska vetenskaper,Region Örebro län,Department of Oncology,Örebro Univ, Dept Oncol, Fac Med & Hlth, Örebro, Sweden
Sabaa, Amal Abu (författare)
Uppsala universitet,Experimentell och klinisk onkologi
visa fler...
Marshall, Katharina (författare)
Uppsala universitet,Experimentell och klinisk onkologi
Hedström, Gustaf (författare)
Uppsala universitet,Experimentell och klinisk onkologi
Flogegård, Max (författare)
Department of Internal Medicine, Falun General Hospital, Falun, Sweden,Falun Gen Hosp, Dept Internal Med, Falun, Sweden
Baecklund, Eva, 1956- (författare)
Uppsala universitet,Reumatologi
Enblad, Gunilla (författare)
Uppsala universitet,Experimentell och klinisk onkologi
visa färre...
 (creator_code:org_t)
Taylor & Francis, 2019
2019
Engelska.
Ingår i: Acta Oncologica. - : Taylor & Francis. - 0284-186X .- 1651-226X. ; 58:8, s. 1170-1177
  • Tidskriftsartikel (refereegranskat)
Abstract Ämnesord
Stäng  
  • Background: Patients with certain autoimmune diseases (AID) have an increased risk of developing diffuse large B-cell lymphoma (DLBCL). However, the occurrence of AID in patients with DLBCL as well as the impact of AID on outcome has not been extensively studied. The main purpose of this study was to establish the occurrence of AIDs in a population-based cohort of DLBCL patients and to compare outcomes in patients with or without AID treated with rituximab(R)-CHOP/CHOP-like treatment. We also aimed to analyse gender differences and the potential role of different AIDs on outcome and the frequency of treatment-associated neutropenic fever. Patients and methods: All adult patients treated 2000-2013 with R-CHOP/CHOP-like treatment for DLBCL in four counties of Sweden were included (n = 612). Lymphoma characteristics, outcome and the presence of AID were obtained through medical records.Results: The number of patients with AID was 106 (17.3%). Thyroid disease dominated (n = 33, 31.1%) followed by rheumatoid arthritis (RA) (n = 24, 22.6%). The proportion of AID was significantly higher in females (59/254, 23.2%) vs. in males (47/358, 13.1%) (p = .001). In the whole cohort there was no difference in event free survival (EFS) or overall survival (OS) between patients with or without AID. However, patients with an AID primarily mediated by B-cell responses (thyroid disorders excluded) had a worse OS (p = .037), which seemed to affect only women. The AID group more often had neutropenic fever after first treatment (16.0% vs 8.7%, p = .034) and those with neutropenic fever had a worse OS (p = .026) in Kaplan-Meier analyses. Conclusion: There is a high prevalence of AID among patients with DLBCL. AIDs categorized as primarily B-cell mediated (in this study mainly RA, systemic lupus erythematosus and Sjögren's syndrome) may be associated with inferior OS. AID patients may be more prone to neutropenic fever compared to patients without concomitant AID.

Ämnesord

MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin -- Cancer och onkologi (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine -- Cancer and Oncology (hsv//eng)

Publikations- och innehållstyp

ref (ämneskategori)
art (ämneskategori)

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy